Tracing Brain Tumors Through Deep Time

Study Purpose

Brain tumors involve different age groups with a wide range of tumor types involving different anatomical compartments of the brain. The evolution of the brain in vertebrates, including the most recent homo species (including humans), has occurred through increasing structural complexity in more evolved species. In the retrospective study, we will investigate the location of the tumors and different structural aspects of skull anatomy in patients with brain tumors. The information will be compared with the anatomical evolution of the brain and skull in vertebrates to look for possible associations, which can provide insights into evolutionary biology.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages N/A and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

• All patients diagnosed with primary brain tumors with available pre/ post-operative or pre-radiation brain images with computed tomography (CT) or magnetic resonance imaging (MRI)

Exclusion Criteria:

  • - CT/ MRI is not available before cranial radiotherapy.
- Artifacts causing distortion of skull (bony) anatomy

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06381531
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Tata Memorial Centre
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

ARCHYA DASGUPTA, MD
Principal Investigator Affiliation Tata Memorial Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries India
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Brain Tumor, Oncology
Additional Details

Patients (pediatric and adults) with a diagnosis (radiological/ histopathological) of primary brain tumors registered in the neuro-oncology disease management group between January 2005 and December 2023 will be screened. Approximately 500-600 patients are expected to be eligible per year with imaging data (approximately 500 patients are treated annually with radiation in our center with available CT data for radiation planning, and another 100-200 patients having pre-operative or post-operative scans). For the above-mentioned time period, data is expected to be available from approximately 10,000 patients, which will be the upper limit of sample size for the current study. The area of the primary tumor (or cavity and residual tumor indicating original location for post-operative data) will be segmented on CT and /or MRI as available. The peritumoral edema will be excluded from the segmented region. The segmentation will be done manually in an initial cohort of approximately 200-500 patients. Subsequently, a machine learning algorithm like a 3D U-net or deep learning-based technique will be trained on the initial data (and validated on the next 100-200 patients to assess algorithm accuracy and robustness) for rapid implementation and segmentation of the large data set. Once brain tumor regions are identified across the entire population, density maps will be generated to reciprocate the location of tumors on a quantitative scale as per age of the patient during diagnosis (age in years as continuous data and categorical data, i.e., age groups, e.g., infants, children, teens, adolescents. adults, and elderly). The generated density maps will be compared with regions of vertebrate brain regions (with openly available literature) across species with regards to the geological scale/ deep time units, e.g., in units of 10-50 million years. Similarly, the skull bony anatomy will be extracted from CT and/ or MRI data (applying techniques like window intensity thresholds without the need for segmentation). Patients with major defects in the calvarial skull from increased intracranial pressure or surgical interventions will be excluded from the analysis of calvarial anthropometry (however, it will be available for skull base anatomy assessment). The organizational patterns will be analyzed using machine learning models and other statistical models like Bayesian statistics and compared with other publicly available normal human populations without brain tumors (adjusting for age, race as applicable), fossil data of vertebrates/ hominids, non-human primates for link recognition. The density maps and anthropometric data will be compared within the entire cohort of patients with brain tumors (from the study) stratified by factors like age (as mentioned earlier), tumor location (e.g., supratentorial vs.#46; infratentorial), tumor grade (benign vs.#46; low grade vs.#46;high grade). The statistical analysis for density maps and anthropometry will be done by sharing anonymized data with collaborators with expertise in similar research from the Indian Statistical Institute (Geological Studies Unit and Interdisciplinary Statistical Research Unit).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Tata Memorial Hospital, Mumbai, Maharashtra, India

Status

Address

Tata Memorial Hospital

Mumbai, Maharashtra, 400012

Site Contact

Dr Archya Dasgupta, MD

[email protected]

91-22-24177000

Stay Informed & Connected